The Redwood Study for Alpha-1 Antitrypsin Deficiency–Associated Liver Disease Is NOW Enrolling!
About the Redwood Study
There is currently no approved treatment available for Alpha-1 Liver Disease. The investigational study drug, TAK-999 (fazirsiran), aims to reduce the production of the abnormal Z-AAT protein and its buildup in the liver. The reduction in levels of the protein may result in a decrease in liver scarring.
The investigational study drug being evaluated alongside the placebo, which appears similar to TAK-999 but contains no active medication, may help researchers understand whether TAK- 999 can reduce liver scarring caused by Alpha-1 Liver Disease.
Who can participate in the Redwood Study?
The Redwood Study (TAK999-3001) has recently updated their eligibility criteria, and you may NOW be eligible if you:
- Are 18 to 75 years of age.
- Have not smoked any substance (defined as not inhaling and exhaling the fumes of a substance) daily for the past 6 months
- Have a confirmed diagnosis of the PiZZ genotype Alpha-1 Liver Disease, or are willing to undergo confirmatory testing at screening.
- Do not have hepatocellular carcinoma (HCC).
All study participants will receive the assigned study treatment, study-related medical exams, and study-related laboratory tests at no cost. Reimbursement for travel expenses may be available. Further details about study support can be discussed with the study team.
If you are interested, a participating research site can confirm a diagnosis of Alpha-1 Liver Disease and genotype, as well as other study criteria to determine your eligibility.
To learn more about the Redwood Study, please click HERE for a study brochure.
